Patterns of Care in Medical Oncology
What percent of your breast cancer patients with node-negative tumors receiving adjuvant chemotherapy receive regimens that include taxanes?
What percent of your breast cancer patients with node-positive tumors receiving adjuvant chemotherapy receive regimens that include taxanes?
In general, when using chemotherapy in the adjuvant setting in patients with smaller, node-negative, ER-positive, HER2-negative tumors, what tends to be the most common regimen you utilize?
In general, when using chemotherapy in the adjuvant setting in patients with node-positive disease, what tends to be the most common regimen you utilize?
When using TAC as adjuvant therapy, how often do you utilize myeloid growth factors preventively?*
(Physicians using AC
docetaxel q3wk as adjuvant chemotherapy): What dose of docetaxel do you generally utilize?*
(Physicians using AC
docetaxel q3wk as adjuvant chemotherapy): How often do you utilize myeloid growth factors preventively with docetaxel?*
Are you aware of data presented by Dr Stephen Jones at the San Antonio Breast Cancer Symposium in December 2005 on the US Oncology trial of adjuvant TC (docetaxel/
cyclophosphamide) versus AC?
Have you utilized the adjuvant TC (docetaxel/
cyclophosphamide) regimen?
How would you compare TC (docetaxel/
cyclophosphamide) to AC?
How would you compare TC (docetaxel/
cyclophosphamide) to AC?
Does the ER status of a tumor generally influence your decision whether to recommend adjuvant chemotherapy for node-positive tumors?
Does the ER status of a tumor generally influence your decision whether to recommend adjuvant chemotherapy for smaller node-negative tumors?
How would you compare the antitumor efficacy of TAC to dose-dense (DD) AC
paclitaxel?
How would you compare the antitumor efficacy of TAC to dose-dense (DD) AC
paclitaxel?
How would you compare the safety and tolerability of TAC to dose-dense (DD) AC
paclitaxel?
Have you ordered the Onco
type
DX assay?
If yes, for how many patients?*
How useful is the Onco
type
DX assay in HER2-negative, ER-positive tumors with negative nodes?*
How useful is the Onco
type
DX assay in HER2-positive, ER-positive tumors with negative nodes?*
For patients with ER-positive, HER2-negative, node-negative tumors, the Onco
type
DX assay should be offered when both the doctor and patient are “on the fence” about whether to use adjuvant chemotherapy.
If CALGB-49907 demonstrates equal efficacy of capecitabine to AC or CMF in the adjuvant setting in elderly women, how often would you utilize adjuvant capecitabine off protocol rather than AC or CMF in elderly women?
docetaxel q3wk as adjuvant chemotherapy): What dose of docetaxel do you generally utilize?*
